NCT03816345 2026-03-18
Nivolumab in Treating Patients With Autoimmune Disorders and Advanced, Metastatic, or Unresectable Cancer
National Cancer Institute (NCI)
Phase 1 Recruiting
National Cancer Institute (NCI)
Gilead Sciences
TG Therapeutics, Inc.
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company